DCGO stock news · DocGo
Get alerts for DCGO
Follow DocGo (DCGO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for DCGODocGo shared its Q3 2026 earnings, showing $73.4 million in sales, up 4% from last year.
NeutralDocGo cut its 2026 sales forecast to about $300 million from $305–310 million. Smaller losses and better margins balance the lower forecast and ongoing losses, leaving a mixed outlook.
DocGo Inc. announces the establishment of a significant definitive agreement (DCGO).
NeutralDocGo Inc. has filed a Form 8-K indicating its entry into a material definitive agreement, which suggests potential strategic developments that could enhance its market position and financial outlook.
DocGo holds Q2 2026 earnings conference call transcript.
NeutralDocGo's Q2 2026 earnings call revealed a mixed financial performance with a revenue decline attributed to the wind down of migrant-related projects, but significant growth in non-migrant revenues and a strategic acquisition of Hicuity Health that is expected to drive future growth and operational efficiencies. This duality in performance creates a complex outlook for investors.
Anticipation builds as DocGo prepares to announce a reduced Q2 loss; analysts fine-tune their predictions prior to the earnings call.
NeutralDocGo is anticipated to report a narrower loss in its upcoming earnings call, which could lead to a positive market reaction. Analysts have adjusted their forecasts, indicating a potential for improved investor sentiment as the company approaches its earnings release.